Boundless Bio, Inc. (BOLD) vs Xilio Therapeutics, Inc. (XLO)
A side-by-side comparison of Boundless Bio, Inc. and Xilio Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BOLD
Boundless Bio, Inc.
$2.57HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
XLO
Xilio Therapeutics, Inc.
$9.00HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — BOLD vs XLO
growth of $100 · dividends reinvested · last 3yBOLD -81.8% (-43.3%/yr)XLO -39.7% (-15.5%/yr)XLO compounded faster over this window
BOLD XLO
BOLD vs XLO: by the numbers
- •XLO is the larger company ($59M vs $58M market cap).
- •Both run net losses; BOLD's is the smaller (0.00% vs -34.06% net margin).
Metrics side by side
Valuation
| Metric | BOLD | XLO |
|---|---|---|
| P/S ratio | N/A | 0.92 |
| P/B ratio | 0.88 | 0.82 |
Profitability
| Metric | BOLD | XLO |
|---|---|---|
| Gross margin | 0.00% | 99.46% |
| Operating margin | 0.00% | -95.92% |
| Net margin | 0.00% | -34.06% |
| ROE | -58.99% | -30.21% |
| ROIC | -43.97% | -26.13% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.